Table 5 AUROC analysis of the biomarkers in endoscopically active vs endoscopically inactive CD and UC patients.

From: Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD

 

CD patients: endoscopically remission vs endoscopically active

UC patients: endoscopically remission vs endoscopically active

AUC [95% CI] [sensitivity; specificity]

p-value

AUC [95% CI] [sensitivity; specificity]

p-value

C6Ma3

1.00 [0.79–1.00] [100-100]

< 0.0001

0.57 [0.38–0.76] [71-45]

0.49

PRO-C6

0.59 [0.33–0.81] [50-86]

0.56

0.52 [0.34–0.69] [71-36]

0.86

CRP

0.87 [0.62–0.98] [91-71]

< 0.0001

0.52 [0.32–0.72] [50-64]

0.81

FC

0.81 [0.60–1.09] [60-100]

0.004

0.85 [0.74–0.95] [69-90]

 < 0.001

C6Ma3 + PRO-C6a

1.00 [0.79–1.00] [100-100]

< 0.0001

0.59 [0.45–0.71] [85-36]

0.41

C6Ma3 + PRO-C6 + confounding factorsa

1.00 [0.79–1.00] [100-100]

< 0.0001

0.66 [0.53–0.78] [67-73]

0.14

 

CD patients: clinically remission vs clinically active

UC patients: clinically remission vs clinically active

AUC [95% CI] [sensitivity; specificity]

p-value

AUC [95% CI] [sensitivity; specificity]

p-value

C6Ma3

0.65 [0.51–0.77] [89-47]

0.053

0.53 [0.53–0.63] [45-71]

0.589

PRO-C6

0.73 [0.60–0.83] [100-46]

0.0002

0.54 [0.44–0.64] [17-96]

0.481

CRP

0.684 [0.56–0.79] [63-75]

0.013

0.59 [0.49–0.68] [38-82]

0.106

FC

0.62 [0.48–0.74] [52-78]

0.147

0.82 [0.73–0.89] [92-70]

< 0.0001

C6Ma3 + PRO-C6a

0.76 [0.63–0.87] [89-58]

< 0.0001

0.57 [0.46–0.67] [33-86]

0.258

C6Ma3 + PRO-C6 + confounding factorsa

0.86 [0.74–0.94] [100-55]

< 0.0001

0.641 [0.54–0.74] [52-76]

0.012

  1. AUROC area under the receiver operating characteristic curve, AUC area under the curve, CI confidence interval.
  2. aLogistic regression model. Confounding factors: age, BMI, gender, and smoking.
Back to article page